Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 9, 2010, Pages 2389-2400

  Carozzi, Francesca M ^a   Tornesello, Maria L ^b   Burroni, Elena ^a   Loquercio, Giovanna ^b   Carillo, Giuseppe ^c   Angeloni, Claudio ^d   Scalisi, Aurora ^e   Macis, Rosalba ^f   Chini, Francesco ^g   Buonaguro, Franco M ^b   Giorgi Rossi, Paolo ^g   Lattanzi, A ^h   Maccallini, V ^h   Donatella, C ^h   Cagliari, F C ^h   Rosalba, M ^h   Pilia, M ^h   Caredda, V ^h   Di Iasi, A ^h   Santarsiere, A ^h   Loredana, C ^h   Manno, M ^h   Santangelo, C ^h   Pini, M T ^h   Giuseppina, G ^h   Isabella, S ^h   Barretta, E ^h   De Santis, V ^h   Filomena, E ^h   Spampinato, G ^h   Cantarella, M A ^h   Lazio, M ^h   Capparucci, P ^h   Marsili, L M ^h   Tufi, M C ^h   Gomez, V ^h   Verrico, G ^h   Schiboni, M L ^h   Pellegrini, A ^h   Bove, E ^h   D'Addetta, A ^h   Placidi, A ^h   Losito, S ^h   Botti, G ^h   Vecchione, A ^h   Confortini, M ^h   Bisanzi, S ^h   Sani, C ^h   Venturini, G ^h   Tinacci, G ^h   Federici, A ^h   more..

^a ISPO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c ASL Caserta 2   (Italy)

^d ASL Teramo   (Italy)

^e ASL Catania   (Italy)

^f Territorial Department of Nephrology and Dialysis   (Italy)

^g Public Health Agency for the Lazio Region   (Italy)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; DNA; PARAFFIN; PRIMER DNA; VIRUS DNA;

ADENOCARCINOMA; ARTICLE; CLINICAL TRIAL; CYTOLOGY; DATA BASE; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MIXED INFECTION; MULTICENTER STUDY; NUCLEIC ACID AMPLIFICATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

EID: 77956504042     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0131     Document Type: Article

References (51)

1. Stanley M. Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol Oncol 2007;107: S19-23.
2. Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007;85:719-26. (Pubitemid 47416724)
3. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101. (Pubitemid 44116919)
4. Ronco G, Giorgi-Rossi P, Carozzi F, et al, New Technologies for Cervical Cancer Screening Working Group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006;7:547-55.
5. Bulkmans N, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;24:1764-72.
6. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97. (Pubitemid 47598401)
7. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10: 672-82.
8. Mayrand MH, Duarte-Franco E, Rodrigues I, et al, Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-88.
9. Intesa del 20 dicembre 2007 tra il Ministero della Salute, le Regioni e le Province Autonome di Trento e Bolzano, "Strategia per l'offerta attiva del vaccino contro l'infezione da HPV in Italia".
10. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14: 1157-64. (Pubitemid 40656461)
11. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer 2009;45:2632-9.
12. Bosch FX, Manos MM, Munoz N, et al, International biological study on cervical cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
13. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24 Suppl 3:S3/26-34.
14. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-5. (Pubitemid 36897943)
15. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer 2003;88:63-73.
16. Sigurdsson K, Sigvaldason H, Gudmundsdottir T, Sigurdsson R, Briem H. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening. Acta Obstet Gynecol Scand 2009;88:27-35.
17. Carozzi FM, Confortini M, Cecchini S, et al. Triage with human papillomavirus testing of women with cytologic abnormalities prompting referral for colposcopy assessment. Cancer 2005;105:2-7.
18. De Francesco MA, Gargiulo F, Schreiber C, Ciravolo G, Salinaro F, Manca N. Detection and genotyping of human papillomavirus in cervical samples from Italian patients. J Med Virol 2005;75:588-92. (Pubitemid 40293527)
19. Del Mistro A, Salamanca HF, Trevisan R, et al. Human papillomavirus typing of invasive cervical cancers in Italy. Infect Agent Cancer 2006;1:9.
20. Gargiulo F, De Francesco MA, Schreiber C, et al. Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women. Virus Res 2007;125:176-82. (Pubitemid 46613818)
21. Sandri MT, Riggio D, Salvatici M, et al. Typing of human papillomavirus in women with cervical lesions: prevalence and distribution of different genotypes. J Med Virol 2009;81:271-7.
22. Sideri M, Cristoforoni P, Casadio C, et al. Distribution of human papillomavirus genotypes in invasive cervical cancer in Italy: a representative, single institution case series. Vaccine 2009;27 Suppl 1:A30-3.
23. Dal Bello B, Spinillo A, Alberizzi P, Cesari S, Gardella B, Silini EM. Time trends of human papillomavirus type distribution in Italian women with cervical intraepithelial neoplasia (CIN). Gynecol Oncol 2009;115:262-6.
24. Agodi A, Barchitta M, La Rosa N, et al. Human papillomavirus infection: low-risk and high-risk genotypes in women in Catania, Sicily. Int J Gynecol Cancer 2009;19:1094-8.
25. Astori G, Arzese A, Pipan C, de Villiers EM, Botta GA. Characterization of a putative new HPV genomic sequence from a cervical lesion using L1 consensus primers and restriction fragment length polymorphism. Virus Res 1997;50:57-63. (Pubitemid 27283254)
26. Rassu M, Bertoloni G, Mengoli C, Peron A, Benedetti P, Palu' G. HPV genotype prevalence in cervical specimens with abnormal cytology: a report from north-east Italy. Scand J Infect Dis 2005;37:476-81. (Pubitemid 41038519)
27. Tornesello ML, Duraturo ML, Botti G, et al, The Italian HPV Working Group. Prevalence of α-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. J Med Virol 2006;78:1663-72.
28. Capra G, Giovannelli L, Bellavia C, et al. HPV genotype prevalence in cytologically abnormal cervical samples from women living in south Italy. Virus Res 2008;133:195-200.
29. Broccolo F, Chiari S, Piana A, et al. Prevalence and viral load of oncogenic human papillomavirus types associated with cervical carcinoma in a population of North Italy. J Med Virol 2009;81: 278-87.
30. Van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002;40:779-87.
31. Bauer HM, Greer CE, Manos MM. Determination of genital human papillomavirus infection by consensus polymerase chain reaction amplification. In: Herrington CS, McGee JOD, editors. Diagnostic molecular pathology, a practical approach. Oxford (United Kingdom): IRL Press; 1992, p. 131-52.
32. Bouvard VA, Baan RA, Straif KA, et al, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group. Lancet Oncol 2009;10:321-2.
33. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
34. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998;153:1731-9.
35. Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508-17.
36. Greer CE, Wheeler CM, Manos MM. Sample preparation and PCR amplification from paraffin-embedded tissues. PCR Methods Appl 1994;3:S113-22.
37. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. Clin Microbiol 1997;35:1304-10.
38. Munoz N, Bosch FX, Castellsague' X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
39. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32.
40. Modena Cancer Registry. Available from: www.rtm.unimo.it.
41. Ciatto S, Grazzini G, Cecchini S, Iossa A. Screening history of incident cases of invasive carcinoma of the cervix. Florence district 1988-1989. Tumori 1993;79:311-3.
42. Zappa M, Visioli CB, Ciatto S, Iossa A, Paci E, Sasieni P. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer 2004;90:1784-6.
43. ISTAT - Unit Struttura e dinamica sociale. Health interview survey: health status and use of health services - years 2004-2005. Roma: ISTAT; 2006.
44. Castellsagué X, Díaz M, de Sanjosé S, et al, International Agency for Research on Cancer on Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15.
45. Prétet JL, Jacquard AC, Carcopino X, et al. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer 2008;122:428-32.
46. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101:475-87.
47. IARC Working Group on the Evaluation of Cancer Preventive Strategies. Cervix cancer screening. IARC Handbooks of Cancer Prevention No. 10. Lyon: IARC; 2005.
48. Usubütün A, Alemany L, Küçükali T, et al. Human papillomavirus types in invasive cervical cancer specimens from Turkey. Int J Gynecol Pathol 2009;28:541-8.
49. Giorgi Rossi P, Bisanzi S, Paganini I, et al.; HPV Prevalence Italian Working Group. Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. BMC Infect Dis 2010;10:214.
50. Mendez F, Munoz N, Posso H, et al, Instituto Nacional de CancerologiaHuman Papillomavirus Study Group. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 2005; 192:1158-65.
51. Rousseau MC, Villa LL, Costa MC, Abrahamowicz M, Rohan TE, Franco E. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Dis 2003;30:581-7.